https://www.yiliao.com/index.php?action=history&feed=atom&title=%E5%8F%8C%E9%87%8D%E6%8A%91%E5%88%B6
双重抑制 - 版本历史
2026-04-09T17:25:39Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E5%8F%8C%E9%87%8D%E6%8A%91%E5%88%B6&diff=316091&oldid=prev
2026年1月28日 (三) 19:05 77921020
2026-01-28T19:05:18Z
<p></p>
<a href="https://www.yiliao.com/index.php?title=%E5%8F%8C%E9%87%8D%E6%8A%91%E5%88%B6&diff=316091&oldid=316089">显示更改</a>
77921020
https://www.yiliao.com/index.php?title=%E5%8F%8C%E9%87%8D%E6%8A%91%E5%88%B6&diff=316089&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-28T19:02:21Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>双重抑制</strong>（Dual Inhibition）是一种药物治疗策略，指同时使用一种双靶点药物或联合两种单靶点药物，对生物体内的两个关键信号分子、受体或代谢途径进行同步阻断。这种策略的核心逻辑在于利用<strong>[[协同效应]]</strong>（Synergy）来克服单一靶点抑制剂常面临的代偿性反馈回路激活及获得性耐药。在精准肿瘤学中，双重抑制主要分为<strong>垂直抑制</strong>（阻断同一通路上下游）和<strong>水平抑制</strong>（阻断平行的代偿通路）。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">双重抑制</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Pharmacological Strategy (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">原理：切断主路与辅路</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th colspan="2" style="padding: 8px 12px; background-color: #e0f2fe; color: #1e40af; text-align: left; font-size: 0.9em; border-top: 1px solid #bae6fd;">策略属性</th><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">核心目标</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">克服耐药, 增强疗效</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">抑制模式 1</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;"><strong>垂直抑制</strong> (Vertical)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">抑制模式 2</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;"><strong>水平抑制</strong> (Horizontal)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">主要风险</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;">叠加毒性 (Toxicity)</td><br />
</tr><br />
<br />
<tr><br />
<th colspan="2" style="padding: 8px 12px; background-color: #e0f2fe; color: #1e40af; text-align: left; font-size: 0.9em; border-top: 1px solid #bae6fd;">典型案例</th><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">黑色素瘤</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">BRAF + MEK 抑制</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569; border-bottom: 1px solid #e2e8f0;">乳腺癌</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">HER2 双靶点阻断</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f8fafc; color: #475569;">免疫治疗</th><br />
<td style="padding: 6px 12px; color: #0f172a;">PD-1 + CTLA-4</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：围堵逃逸路径</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
肿瘤细胞具有极强的适应性，单一靶点的封锁往往导致“旁路激活”。双重抑制通过以下两种主要拓扑结构来破坏这种适应性：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>垂直抑制 (Vertical Inhibition)：</strong> <br />
<br>在同一条信号通路上阻断两个不同的节点（如上游和下游）。<br />
<br><em>例子：</em> 在 MAPK 通路中同时抑制 <strong>BRAF</strong> 和 <strong>MEK</strong>。<br />
<br><em>目的：</em> 防止因解除负反馈调节而导致的通路再激活（Reactivation）。</li><br />
<br />
<li style="margin-bottom: 12px;"><strong>水平抑制 (Horizontal Inhibition)：</strong> <br />
<br>同时阻断两条功能平行或互补的信号通路。<br />
<br><em>例子：</em> 同时抑制 <strong>PI3K</strong> 通路和 <strong>MAPK</strong> 通路，或同时阻断 <strong>HER2</strong> 和 <strong>EGFR</strong>。<br />
<br><em>目的：</em> 阻断肿瘤细胞利用替代通路维持生存（Survival Switching）。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床应用范例</h2><br />
<br />
<div style="overflow-x: auto; margin: 20px auto;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f1f5f9; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">适应症</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569; width: 30%;">组合方案</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">机制逻辑</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">BRAF V600E 黑色素瘤</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">Dabrafenib (BRAF) + Trametinib (MEK)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>垂直抑制</strong>。相比单药，显著推迟了耐药性的产生并提高了总生存期。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">HER2+ 乳腺癌</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">Trastuzumab + Pertuzumab</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>双位点阻断</strong>。分别结合 HER2 的结构域 IV 和 II，更彻底地阻断 HER2 二聚化信号。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">晚期肾癌 (RCC)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">Lenvatinib (VEGFR) + Everolimus (mTOR)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>水平抑制</strong>。同时切断血管生成信号和细胞代谢信号。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">挑战与困境：双刃剑</h2><br />
<br />
<div style="background-color: #f0f9ff; border-left: 5px solid #1e40af; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<h3 style="margin-top: 0; color: #1e40af; font-size: 1.1em;">1+1 > 2 的代价</h3><br />
<p style="margin-bottom: 0; text-align: justify; font-size: 0.95em; color: #334155;"><br />
虽然疗效增强，但双重抑制常伴随<strong>毒性叠加</strong>。例如，双重免疫检查点抑制（PD-1 + CTLA-4）会导致更频繁和严重的免疫相关不良反应（irAEs），如结肠炎和肺炎。此外，双重抑制方案的<strong>经济成本</strong>也是限制其广泛应用的重要因素。<br />
</p><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献 [Academic Review]</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Larkin J, et al. (2015).</strong> <em>Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.</em> <strong>[[New England Journal of Medicine]]</strong>. <br><br />
<span style="color: #475569;">[点评]：经典的双重免疫抑制临床试验，确立了“O+Y”组合在黑色素瘤中的地位。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Baselga J, et al. (2012).</strong> <em>Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer.</em> <strong>[[New England Journal of Medicine]]</strong>. <br><br />
<span style="color: #475569;">[点评]：CLEOPATRA 研究，证明了双重 HER2 阻断策略显著延长了患者的生存期。</span><br />
</p><br />
<br />
<p style="margin: 12px 0;"><br />
[3] <strong>Rozengurt E, et al. (2014).</strong> <em>Crosstalk between insulin/IGF-1 receptors and GPCR signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer.</em> <strong>[[Clinical Cancer Research]]</strong>. <br><br />
<span style="color: #475569;">[点评]：探讨了信号通路间串扰（Crosstalk）机制，为水平双重抑制提供了理论基础。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
双重抑制 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">核心理论</td><br />
<td style="padding: 10px 15px; color: #334155;">[[协同效应]] (Synergism) • [[合成致死]] (Synthetic Lethality) • [[负反馈回路]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">单分子双靶</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Lapatinib]] (EGFR/HER2) • [[Sunitinib]] (多靶点RTK) • [[双特异性抗体]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">耐药机制</td><br />
<td style="padding: 10px 15px; color: #334155;">[[通路串扰]] (Crosstalk) • [[旁路激活]] (Bypass) • [[靶点突变]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
77921020